Form 4: Exelixis EVP Sells $2.06M in Stock Under 10b5-1 Plan

Exelixis' EVP of Research and Development, Dana Aftab, reported the pre-planned sale of 48,383 shares of common stock for approximately $2.06 million.

Summary

• Dana Aftab, Executive Vice President of Research and Development at Exelixis, Inc. (EXEL), reported a transaction involving the sale of company stock.
• The transaction occurred on November 11, 2025, and involved the disposition of 48,383 shares of Exelixis Common Stock.
• The shares were sold at a weighted average price of $42.50 per share, with individual transaction prices ranging from $42.50 to $42.58.
• The total value of the shares sold is approximately $2,056,277.50.
• This sale was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan, indicating it was scheduled in advance.
• Following the transaction, Dana Aftab directly beneficially owns 664,778 shares, which includes 431,306 shares underlying restricted stock units (RSUs).
• An additional 5,835 shares are indirectly beneficially owned through the Exelixis, Inc. 401(k) Plan, as per a plan statement dated November 10, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive because the sale was executed under a pre-arranged 10b5-1 plan. This mitigates concerns that the executive is selling based on negative undisclosed information, positioning it as a routine liquidity event rather than a change in outlook.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, which indicates the sale was pre-scheduled and not based on new, non-public information, mitigating concerns about insider sentiment.

Negatives

• An executive selling a significant number of shares, even if pre-planned, can sometimes be perceived negatively by some investors, potentially leading to short-term negative sentiment.

Risks

• There is a potential for negative investor sentiment if the pre-planned nature of the sale is overlooked or misunderstood by the market.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice in the biotechnology and pharmaceutical industries. These pre-arranged sales allow executives to manage personal finances and diversify holdings in a compliant manner, and are generally viewed as less indicative of management's sentiment about future company performance compared to unscheduled sales.

Stakeholder Impact

• Shareholders may interpret the insider sale, even if pre-planned, with varying degrees of concern or neutrality, potentially influencing short-term trading sentiment.

Key Dates

Recommendation

The sale by an executive, while significant in value, was conducted under a Rule 10b5-1 pre-arranged trading plan. This indicates the transaction was scheduled in advance and not based on new, non-public information, thus it does not necessarily signal a change in the executive's confidence in the company's future prospects. Investors should view this as a routine liquidity event rather than a bearish signal, warranting a 'hold' recommendation based solely on this filing.

Keywords

Exelixis, EXEL, Form 4, Insider Sale, Stock Transaction, Dana Aftab, 10b5-1 Plan, Biotechnology, Pharmaceuticals